Neurocrine Biosciences, Inc. (NBIX)
USD 91.52
(-4.32%)
USD 91.52
(-4.32%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 38.3 Million USD | 9.12% |
| 2022 | 35.1 Million USD | 15.08% |
| 2021 | 30.5 Million USD | 8.93% |
| 2020 | 28 Million USD | 61.96% |
| 2019 | 17.28 Million USD | 59.13% |
| 2018 | 10.86 Million USD | 134.9% |
| 2017 | -31.12 Million USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 100.0% |
| 2013 | -23 Thousand USD | 99.84% |
| 2012 | -14.08 Million USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 42.5 Million USD | 14.25% |
| 2024 Q1 | 37.2 Million USD | -2.87% |
| 2024 Q3 | 45.8 Million USD | 7.76% |
| 2023 Q2 | 31.7 Million USD | -5.09% |
| 2023 Q1 | 33.4 Million USD | -4.84% |
| 2023 Q3 | 28.8 Million USD | -9.15% |
| 2023 FY | 38.3 Million USD | 9.12% |
| 2023 Q4 | 38.3 Million USD | 32.99% |
| 2022 FY | 35.1 Million USD | 15.08% |
| 2022 Q2 | 29.3 Million USD | 1.03% |
| 2022 Q3 | 37 Million USD | 26.28% |
| 2022 Q1 | 29 Million USD | -4.92% |
| 2022 Q4 | 35.1 Million USD | -5.14% |
| 2021 Q3 | 25.5 Million USD | -9.89% |
| 2021 Q2 | 28.3 Million USD | -5.98% |
| 2021 Q1 | 30.1 Million USD | 7.5% |
| 2021 Q4 | 30.5 Million USD | 19.61% |
| 2021 FY | 30.5 Million USD | 8.93% |
| 2020 Q3 | 20.6 Million USD | -6.36% |
| 2020 Q1 | 21.2 Million USD | 22.63% |
| 2020 Q2 | 22 Million USD | 3.77% |
| 2020 FY | 28 Million USD | 61.96% |
| 2020 Q4 | 28 Million USD | 35.92% |
| 2019 Q3 | 10.79 Million USD | -10.15% |
| 2019 Q1 | 13.01 Million USD | 19.75% |
| 2019 Q4 | 17.28 Million USD | 60.1% |
| 2019 Q2 | 12.01 Million USD | -7.62% |
| 2019 FY | 17.28 Million USD | 59.13% |
| 2018 Q1 | - USD | 100.0% |
| 2018 FY | 10.86 Million USD | 134.9% |
| 2018 Q4 | 10.86 Million USD | 79.45% |
| 2018 Q3 | 6.05 Million USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 FY | -31.12 Million USD | 0.0% |
| 2017 Q4 | -31.12 Million USD | -12962.4% |
| 2017 Q3 | 242 Thousand USD | 89.06% |
| 2017 Q2 | 128 Thousand USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2015 Q1 | -30.03 Million USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q2 | - USD | 100.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 100.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 100.0% |
| 2014 Q1 | -1.87 Million USD | -8043.48% |
| 2014 Q2 | -2.91 Million USD | -55.85% |
| 2013 FY | -23 Thousand USD | 99.84% |
| 2013 Q4 | -23 Thousand USD | 0.0% |
| 2013 Q1 | - USD | 100.0% |
| 2013 Q2 | -38 Thousand USD | 0.0% |
| 2013 Q3 | - USD | 100.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | -14.08 Million USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q4 | -14.08 Million USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 100.0% |
| 2010 Q3 | -124.97 Million USD | 4.88% |
| 2010 Q2 | -131.38 Million USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Cosmos Health Inc. | 4.78 Million USD | -699.74% |
| Safety Shot Inc | 1.86 Million USD | -1948.515% |
| Bright Green Corporation | - USD | -Infinity% |
| Embecta Corp. | 152.1 Million USD | 74.819% |
| ANI Pharmaceuticals, Inc. | 111.19 Million USD | 65.556% |
| Aquestive Therapeutics, Inc. | 6.76 Million USD | -465.815% |
| Collegium Pharmaceutical, Inc. | 32.33 Million USD | -18.458% |
| Dynavax Technologies Corporation | 53.29 Million USD | 28.129% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 41.636% |
| Intra-Cellular Therapies, Inc. | 11.64 Million USD | -228.84% |
| Pacira BioSciences, Inc. | 104.35 Million USD | 63.298% |
| PainReform Ltd. | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -567.858% |
| Sunshine Biopharma, Inc. | 5.73 Million USD | -567.858% |
| SCYNEXIS, Inc. | - USD | -Infinity% |
| China SXT Pharmaceuticals, Inc. | 809.75 Thousand USD | -4629.814% |
| Journey Medical Corporation | 10.2 Million USD | -275.269% |
| Alpha Teknova, Inc. | 11.59 Million USD | -230.343% |
| Procaps Group, S.A. | 96.83 Million USD | 60.447% |
| Theratechnologies Inc. | 6.06 Million USD | -531.388% |
| Harrow Health, Inc. | 10.86 Million USD | -252.443% |
| Sonoma Pharmaceuticals, Inc. | 2.71 Million USD | -1308.606% |
| Biofrontera Inc. | 10.9 Million USD | -251.118% |
| DURECT Corporation | 2.21 Million USD | -1626.003% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 50.522% |
| Cronos Group Inc. | 30.33 Million USD | -26.24% |
| OptiNose, Inc. | 8.05 Million USD | -375.658% |
| Ironwood Pharmaceuticals, Inc. | 1.00 USD | -3829999900.0% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 5.69 Million USD | -572.044% |
| Organogenesis Holdings Inc. | 28.25 Million USD | -35.561% |
| Guardion Health Sciences, Inc. | 2.67 Million USD | -1330.646% |
| Cumberland Pharmaceuticals Inc. | 4.6 Million USD | -730.918% |
| Radius Health, Inc. | 278.64 Million USD | 86.255% |
| Universe Pharmaceuticals INC | 3.34 Million USD | -1045.586% |
| ProPhase Labs, Inc. | 3.84 Million USD | -897.136% |
| Phibro Animal Health Corporation | 265.91 Million USD | 85.597% |
| Procaps Group S.A. | 96.83 Million USD | 60.447% |
| Alvotech | 74.43 Million USD | 48.544% |
| TherapeuticsMD, Inc. | - USD | -Infinity% |
| Viatris Inc. | 3.46 Billion USD | 98.896% |
| Rockwell Medical, Inc. | 5.87 Million USD | -552.359% |
| Aytu BioPharma, Inc. | 12.63 Million USD | -203.174% |
| SIGA Technologies, Inc. | 64.21 Million USD | 40.36% |
| Tilray Brands, Inc. | 252.08 Million USD | 84.807% |
| Lifecore Biomedical, Inc. | 39.97 Million USD | 4.2% |
| Shineco, Inc. | 1.58 Million USD | -2311.042% |
| PetIQ, Inc. | 159.3 Million USD | 75.959% |
| Regencell Bioscience Holdings Limited | -152.77 Thousand USD | 25169.054% |
| Incannex Healthcare Limited | -10.01 Million USD | 482.426% |
| Alimera Sciences, Inc. | 1.87 Million USD | -1938.318% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 37.68 Million USD | -1.629% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Petros Pharmaceuticals, Inc. | 1.61 Million USD | -2278.304% |
| Clever Leaves Holdings Inc. | 4.48 Million USD | -754.339% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -14957.873% |
| Avadel Pharmaceuticals plc | 10.38 Million USD | -268.979% |
| Hempacco Co., Inc. | 2.54 Million USD | -1406.316% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 74.43 Million USD | 48.544% |
| Eagle Pharmaceuticals, Inc. | 47.79 Million USD | 19.864% |
| Lantheus Holdings, Inc. | 64.02 Million USD | 40.183% |
| Currenc Group, Inc. | 732.91 Thousand USD | -5125.737% |
| Kamada Ltd. | 87.74 Million USD | 56.352% |
| Indivior PLC | 141.79 Million USD | 72.99% |
| Evoke Pharma, Inc. | 481.84 Thousand USD | -7848.697% |
| Flora Growth Corp. | 8.5 Million USD | -350.165% |
| Cyclo Therapeutics, Inc. | 254.35 Thousand USD | -14957.873% |
| Evolus, Inc. | 10.99 Million USD | -248.245% |
| HUTCHMED (China) Limited | 50.25 Million USD | 23.793% |
| Amphastar Pharmaceuticals, Inc. | 105.83 Million USD | 63.811% |
| Akanda Corp. | 1.28 Million USD | -2876.158% |